PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients| Stephy publishers

 


Abstract

Purpose: To evaluate the influence of nadir prostate-specific antigen (PSA) level and time to PSA nadir following androgen deprivation therapy (ADT)on disease progression of castration-resistant prostate cancer (CRPC) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC).

Patients and methods: A total of 90 patients with metastatic, hormone-sensitive prostate cancer treated with androgen deprivation therapy in our hospital were included in our retrospective study. Patients’ characteristics, PSA at PADT initiation (initial PSA), PSA nadir, TTN, follow up time, CRPC event were analyzed using Kaplan-Meier analysis and Cox regression model.

Results: At a median follow-up of 12 months, 57 patients (63.3%) showed disease progression of CRPC Both PSA nadir and time to PSA nadir (TTN) was independent and significant predictors of CRPC event. Patients with higher PSA nadir (≥0.2ng/dL) and shorter time to PSA nadir (TTN <6 months) had significant shorter time to CRPC. Meanwhile, the Gleason score, age and initial PSA werenot significant predictors of disease progression. In the combined analyses showed patients with higher of PSA nadir and shorter TTN had significantly higher risk for CRPC event compared to lower PSA nadir and longer TTN (HR 69.243, p-value< 0.001)

Conclusion: We concluded that both higher PSA nadir and shorter time to PSA nadir are significant predictors of CRPC in patients with metastatic, hormone-sensitive prostate cancer receiving ADT.


Keywords
Metastatichormone sensitive prostate cancer, Androgen deprivation therapy, Time to PSA nadir, PSA nadir, Castration resistant prostate cancer


Introduction

Androgen-deprivation therapy (ADT) is the most effective systemic therapy in patients who have hormone-sensitive prostate cancer. PSA levels remain low or undetectable for years.1 However, the emergence of castration-resistant prostate cancer (CRPC) is typical.2 Treatment options for CRPC remain limited and the prognosis of patient with CRPC is dismal.3 With hormone treatment of advanced prostate cancer, PSA level increases 6 to 12 months before definitive radiological or clinical of disease progression.4-7 Median survival in patients with CRPC is approximately 24 to- 36months.1 The accurate prediction parameter of disease progression might be used to evaluate prognosis of disease and benefit from aggressive or novel treatment. PSA kinetics have been used as useful prognostic indicators for disease or survival in different clinical setting including radical prostatectomy and external beam radiation therapy.8-11 Nevertheless, its prognostic ability for those receiving ADT for metastatic, hormone-sensitive prostate cancer is not well understood. The PSA nadir has been suggested to be the most significant predictor of progression to CRPC in many studies. 12-17 However, the time to PSA nadir (TTN) is still controversy. Some earlier studies suggested that shorter TTN correlated with longer time of progression-free survival.4,5,18-20 But many recent studies suggested that longer TTN correlated with longer time of progression-free survival.1,16,17,21,22 In our study, we retrospectively reviewed our single-center treatment of metastatic-hormone sensitive prostate cancer (mHSPC) patients to evaluate the prognostic ability of PSA nadir and TTN in both individual and interactive effect on disease progression to CRPC.


Materials and Methods

As a retrospective cohort study. The database in Thammasat university hospital between July 2012 and December 2019. A total of 90 patients who diagnosed metastatic-hormone sensitive prostate cancer and received androgen-deprivation therapy (ADT) such as gonadotropin-releasing hormone (GnRH) agonist plus anti-androgen, GnRH antagonist or bilateral orchiectomy were included in this study. GnRHagonist combined with anti-androgen were used in 23 patients (25.5%), GnRH antagonist was used in 20 patients (22.2%) and bilateral orchiectomy was used in 47 patients (52.2%). Patients were followed up a progression of disease by PSA every 3 months thereafter. We determined the study size by using a hazard ratio = 4.3,21 CRPC event = 30%, Patients who loss to follow-up=10%, power 80%, p=0.05 and two-sided test. We found that the study size was 42 patients. Predictors used in multivariate analysis (Cox’s proportional hazard model) were Gleason score, initial PSA, PSA nadir, TTN (add 10 patients per predictor). Thus, the study size was appropriately at least 82 patients.


To read more #Nephrology
https://www.stephypublishers.com/tunr/fulltext/TUNR.MS.ID.000504.php


#Openaccessjournals
https://www.stephypublishers.com/

Comments

Popular posts from this blog

Journal of Psychological Science and Research - (JPSSR) | Stephy Publishers